A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)

Study type

• Study topic:
  Human medicinal product
• Study topic, other:
  Vaccine Effectiveness
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medicinal product name:
  ABRYSVO
• Medicinal product name, other:
  Bivalent respiratory syncytial virus (RSV) prefusion F subunit vaccine
• Anatomical Therapeutic Chemical (ATC) code:
  (J07BX05) respiratory syncytial virus vaccines

  respiratory syncytial virus vaccines
• Medical condition to be studied:
  Respiratory syncytial virus infection

Population studied

• Short description of the study population:
  The study population will include Danish adults aged 60+ year of age.
• Age groups:
  • Adults (46 to < 65 years)
  • Elderly (≥ 65 years)

    • Adults (65 to < 75 years)
    • Adults (75 to < 85 years)
    • Adults (85 years and over)
• Special population of interest:
  Immunocompromised